These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 10892758)

  • 1. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
    Wallentin L; Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E
    Lancet; 2000 Jul; 356(9223):9-16. PubMed ID: 10892758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
    Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.
    Lancet; 1999 Aug; 354(9180):708-15. PubMed ID: 10475181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.
    Lancet; 1999 Aug; 354(9180):701-7. PubMed ID: 10475180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
    Wallentin L; Husted S; Kontny F; Swahn E
    Am J Cardiol; 1997 Sep; 80(5A):61E-63E. PubMed ID: 9296473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
    Wallentin L
    Haemostasis; 2000; 30 Suppl 2():108-13; discussion 106-7. PubMed ID: 11251353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
    Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E; Wallentin L;
    Lancet; 2006 Sep; 368(9540):998-1004. PubMed ID: 16980115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials.
    Damman P; van Geloven N; Wallentin L; Lagerqvist B; Fox KA; Clayton T; Pocock SJ; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ
    JACC Cardiovasc Interv; 2012 Feb; 5(2):191-9. PubMed ID: 22361604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial.
    Janzon M; Levin LA; Swahn E;
    Heart; 2003 Mar; 89(3):287-92. PubMed ID: 12591833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators.
    Lagerqvist B; Säfström K; Ståhle E; Wallentin L; Swahn E;
    J Am Coll Cardiol; 2001 Jul; 38(1):41-8. PubMed ID: 11451294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study.
    Wallentin L; Lindhagen L; Ärnström E; Husted S; Janzon M; Johnsen SP; Kontny F; Kempf T; Levin LÅ; Lindahl B; Stridsberg M; Ståhle E; Venge P; Wollert KC; Swahn E; Lagerqvist B;
    Lancet; 2016 Oct; 388(10054):1903-1911. PubMed ID: 27585757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving outcomes in acute coronary syndromes--the FRISC II trial.
    Kontny F
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I3-7. PubMed ID: 11286312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute coronary syndromes: extending medical intervention for five days before proceeding to revascularization.
    Holmes DR
    Am J Cardiol; 2000 Dec; 86(12B):36M-41M. PubMed ID: 11206017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease.
    Janzon M; Levin LA; Swahn E
    Eur Heart J; 2002 Jan; 23(1):31-40. PubMed ID: 11741360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
    Swahn E; Wallentin L
    Am J Cardiol; 1997 Sep; 80(5A):25E-29E. PubMed ID: 9296466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy.
    Diderholm E; Andrén B; Frostfeldt G; Genberg M; Jernberg T; Lagerqvist B; Lindahl B; Venge P; Wallentin L;
    Am Heart J; 2002 May; 143(5):760-7. PubMed ID: 12040335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
    Lindahl B; Venge P; Wallentin L
    J Am Coll Cardiol; 1997 Jan; 29(1):43-8. PubMed ID: 8996293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial.
    TIME Investigators
    Lancet; 2001 Sep; 358(9286):951-7. PubMed ID: 11583747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study.
    Lagerqvist B; Husted S; Kontny F; Näslund U; Ståhle E; Swahn E; Wallentin L;
    J Am Coll Cardiol; 2002 Dec; 40(11):1902-14. PubMed ID: 12475448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
    Husted SE; Wallentin L; Lagerqvist B; Kontny F; Ståhle E; Swahn E
    Eur Heart J; 2002 Aug; 23(15):1213-8. PubMed ID: 12127923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.